First Read starts the holiday with news that Pfizer and Allergan have reached a $150 [...]Continue
First Read kicks off your morning with news that ISIS threatens New York City in [...]Continue
The Dementia Discovery Fund, which focuses on developing new dementia treatments, has raised $100 million. DDF’s backers include UK Government’s Department of Health, Alzheimer’s Research UK, Biogen, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, Pfizer and Takeda. SV Life Sciences is managing the fund.Continue
First Read starts your morning with news of Apple in talks to launch a streaming [...]Continue
In Second Opinion, Amazon is in talks to buy some RadoShack stores, the fear that [...]Continue
San Francisco-based early-stage biotech firm Circle Pharma said Monday that it has secured an undisclosed amount of seed funding. The investors were Pfizer and QB3’s seed-stage venture fund Mission Bay Capital.Continue
Accelerator Corp. said Tuesday that it has raised $51.1 million in the first close of its fourth fund. The pool’s investors include Alexandria Venture Investments, ARCH Venture Partners, WRF Capital, Eli Lilly, Harris & Harris Group, Johnson & Johnson Development Corp., The Partnership Fund for New York City and Pfizer Venture Investments. Based in Seattle and New York City, Accelerator Corp is a biotech investment firm.Continue
Polaris Partners, which is in the market for a $400 million seventh fund, has brought [...]Continue
KKR has made back roughly 80 percent of its investment in Capsugel in less than [...]Continue
Investor support for large acquisitions and a desire to trump rivals in consolidating markets have [...]Continue
San Diego-based biotech startup Solstice Biologics, which is backed by venBio and Aeris Capital, has hired Dr. Lou Tartaglia as president and CEO. Tartaglia has also been added to the firm’s board of directors. Also, the firm has named John Borgeson as chief financial officer. Previously, Tartaglia worked at Third Rock Ventures where he was a partner while Borgeson was vice president of finance for Pfizer‘s biotherapeutic and bioinnovation center.Continue
GlaxoSmithKline (GSK.L) has invited private equity firms to consider making offers for a range of [...]Continue
AstraZeneca has rejected a sweetened and final offer from Pfizer, writes Reuters. The rebuff came nine hours after Pfizer said it had raised its takeover offer to 55 pounds a share, or around 70 billion pounds ($118 billion) in total, and would walk away if AstraZeneca did not accept it, writes Reuters.Continue
U.S. drugmaker Pfizer Inc is working on its next move in a potential $100 billion battle for Britain’s AstraZeneca Plc after having two bids rejected, as deal-making grips the healthcare industry, Reuters reported.Continue
Jeff Kindler, the former Chairman and CEO of Pfizer, has joined Lux Capital as a venture partner. Kindler will help identify new healthcare investment opportunities and work with Lux portfolio companies. PRESS RELEASE Lux Capital, a leading venture capital firm, today announced that former Pfizer Chairman and CEO Jeff Kindler joined the firm as a […]Continue
Global M&A deal value surged this week while PE transactions turned in some of their lowest numbers.Continue
Pfizer is to divest its nutrition business to Nestlé for $11.85 billion in cash. Pfizer’s Nutrition business recorded revenues of approximately $2.1 billion in 2011, an increase of 15% versus 2010. PRESS RELEASE Pfizer today announced that it has entered into an agreement to divest its Nutrition business to Nestlé for $11.85 billion in cash. […]Continue
(Reuters) – A rogue surgeon injects stem cells from a fetus into a sick man’s brain. The cells morph and form body parts. When the man dies, the pathologist finds cartilage, skin and bone clumped in his brain.
The scene is not from a horror movie; it happened to Max Truex, a former Olympic runner who suffered from Parkinson’s disease. The case sent a chill through the scientific community when it came to light 15 years ago and typifies some of the hurdles researchers have faced while trying to bring stem cell therapies to the market.
Now, it appears, their efforts are closer than ever to paying off.
Dozens of adult stem cell treatments are moving through clinical trials and showing early success, raising hopes that some could reach the market within five years.
“It will only take a few successes to really change the …Continue